Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) generates news at the intersection of biotechnology, AI, and cardiovascular medicine. As an artificial intelligence-powered precision cardiovascular medicine company, its announcements often focus on clinical validation of its genetic-epigenetic tests, partnerships with healthcare providers and community organizations, reimbursement milestones, and expansion into new markets.
News coverage for Cardio Diagnostics frequently highlights developments related to its Epi+Gen CHD and PrecisionCHD blood tests for coronary heart disease. Articles include updates on clinical data, such as studies demonstrating PrecisionCHD’s ability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA), as well as research collaborations that explore inflammation-driven CHD and the use of anti-inflammatory medications alongside molecular testing.
Investors and clinicians following CDIO can also expect news about reimbursement and regulatory progress, including gapfill payment rates from the Centers for Medicare and Medicaid Services and the assignment of CPT Proprietary Laboratory Analysis codes. Additional coverage includes provider network expansion across concierge, functional medicine, and primary care practices in multiple U.S. regions, and community health partnerships with organizations such as YMCA of East Tennessee and Southdale YMCA to bring heart health education and advanced testing to local communities.
International and intellectual property developments are another key news theme. Cardio Diagnostics has reported patents in jurisdictions including Japan, which support its global intellectual property strategy, and has announced its first expansion outside the United States through an agreement to launch the PrecisionCHD test in India with Aimil Ltd. and Dr. Lal PathLabs. For readers interested in how AI, epigenetics, and genetics are being applied to coronary heart disease, the CDIO news stream offers ongoing updates on clinical, commercial, and strategic milestones.
Cardio Diagnostics Holdings (Nasdaq: CDIO) has partnered with Healing Sanctuary Clinic in Idaho to offer the Epi+Gen CHD Precision Cardiovascular Test. This innovative test leverages epigenetics, genetics, and AI to identify patients at risk for coronary heart disease. The collaboration aims to enhance patient outcomes and reduce heart disease incidence in the U.S. Cardio Diagnostics emphasizes its commitment to making precision diagnostics accessible and effective in heart disease prevention.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) will attend the JP Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. This significant event gathers healthcare leaders to share insights and innovations. Cardio Diagnostics aims to showcase its advancements in cardiovascular disease prevention and detection, connecting with strategic partners, investors, and analysts. The company is committed to enhancing personalized healthcare through its AI-driven Integrated Genetic-Epigenetic Engine, striving to become a key player in medical technology.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) has partnered with Houston Concierge Medicine to offer the Epi+Gen CHD precision cardiovascular disease test, targeting executives in Houston, Texas. This test utilizes epigenetics and AI to identify coronary heart disease risks, enhancing preventive care for high-stress professionals. The collaboration highlights a growing trend of executive physicals aimed at long-term health benefits, potentially reducing future medical costs and absenteeism. The Houston practice emphasizes its commitment to best-in-class diagnostic solutions, addressing heart health concerns among its clientele.
Cardio Diagnostics (Nasdaq: CDIO) has been recognized in Fast Company’s Next Big Things in Tech list, which highlights transformative technology breakthroughs. This year features 83 technological advancements from various sectors, showcasing innovations that could impact businesses and society within five years. The company focuses on cardiovascular disease prevention using integrated epigenetics-genetics and AI. The recognition emphasizes Cardio’s commitment to improving personalized healthcare.
Fast Company’s Winter 2022/2023 issue is available online.
Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) announced its sponsorship of the Illinois Association of Medicaid Health Plans’ Annual Conference from November 14-16, 2022, at the Hyatt Lodge Hotel in Oakbrook. CEO Meesha Dogan, PhD, will present on optimizing health equity initiatives in chronic disease management. The conference aims to address critical patient and reimbursement considerations for vulnerable populations, emphasizing equitable access to care to improve health outcomes and reduce healthcare resource consumption.
Cardio Diagnostics (Nasdaq: CDIO) has been accepted into the Forbes Technology Council, an exclusive community for top technology executives. CEO Meesha Dogan, PhD, emphasized that the company's innovative approach combines epigenetics, genetics, high-throughput computing, and AI to enhance early detection and prevention of cardiovascular disease. This prestigious membership is based on Dr. Dogan's significant professional achievements and aims to further strengthen the company's impact in the cardiovascular health sector.
Cardio Diagnostics Holdings (NASDAQ: CDIO) is sponsoring Becker’s Hospital Review 11th Annual Meeting from November 7-10, 2022, in Chicago. CEO Meesha Dogan will present on epigenetics in heart disease at booth #120. The conference attracts over 1,000 healthcare leaders to address critical issues in hospital management. Cardio’s mission focuses on advancing cardiovascular disease detection and treatment through its proprietary Integrated Genetic-Epigenetic Engine, developed at the University of Iowa. This technology aims to enhance personalized cardiovascular care and risk stratification.